You need to enable JavaScript to run this app.
FDA finalizes guidance on metastasis-free survival as an endpoint for prostate cancer trials
Regulatory News
Michael Mezher
Clinical Trials
North America
Pharmaceuticals
Regulatory NewsMichael Mezher
Clinical TrialsNorth AmericaPharmaceuticalsRegulatory NewsMichael MezherClinical TrialsNorth AmericaPharmaceuticals